Sweden – Health and social work services – Drift av Vårdbostäderna Ekollongatan och Skräddaregården

Poland – Pharmaceutical products – Dostawa produktów leczniczych wykorzystywanych przez oddziały szpitala, leki stosowane w ramach programów lekowych oraz chemioterapii (część 1)

Italy – Vascular prostheses – ENDOPROTESI VASCOLARI ADDOMINALI E (KIT EMERGENZE) III EDIZIONE

Expected Outcome: Project results are expected to contribute to all the following expected outcomes: Advance in the achievement of the Strategic Energy Technology (SET) Plan’s research and innovation priorities and targets for wind energy; Efficient and effective support to wind energy research and innovation through alignment and cooperation among different actors, avoiding fragmentation of efforts; Energy producers and consumers benefit from increased performance of wind energy technologies with the focus on efficiency and flexibility, reduced cost, improved reliability and sustainability, operation and maintenance, safety, robustness and security during all stages of the lifetime of a wind energy farm from installation, operation and maintenance to decommissioning; Increased contribution of wind energy to the energy system, with minimal impacts on health and the environment (notably biodiversity and pollution) and at the lowest possible cost. Scope: The action contributes to address the Strategic Energy Technology (SET) Plan’s research and innovation priorities and targets for wind energy, as defined by the Implementation Working Group (IWG) on wind energy, the European…

Expected Outcome: Project results are expected to contribute to all of the following expected outcomes: Increased evidence of factors such as physiological, behavioural, social, environmental and cultural that influence how different user and demographic groups perceive and use smart, secured, integrated energy efficient building systems, and how it affects the building whole-life cycle and energy savings, as well as occupant satisfaction, health and well-being; The design and operation of smart building systems and smart buildings are improved making them more user-friendly and effective. Scope: Significant investments have been made in developing hardware and software for smart buildings. There is still limited understanding how smart buildings solutions impact the energy performance of buildings and users’ comfort in practice. Research is required on the technical, social, and economic factors that influence how different groups – defined by their social, educational, age, and financial status – use and interact with smart buildings and systems. The whole-life cycle impacts of smart building have to be better understood, from design and construction to operation, maintenance,…

Expected Outcome: Successful proposals will contribute to the implementation of the EU initiative on Biotechnology and Biomanufacturing and the EU Life Sciences Strategy as well as the updated EU Bioeconomy Strategy, the upcoming EU Biotechnology Act and EU Circular Economy Act. Projects’ results are expected to contribute to the following expected outcomes: Full industrial scale biorefinery and related value chain(s) for the production of nutritional food ingredients. Resilience and strategic autonomy of EU food sectors via diversification of nutritional food ingredient sources. Increased environmental sustainability of food sectors (e.g. addressing issues like land use, water use, energy consumption, nitrogen cycle, other nutrients, etc.). Improved consumers awareness and acceptance of nutritional food ingredients from alternative sources, contributing to sustainable healthy diets. Scope: Human nutrition is a key area where the bio-based industries can play an important role in addressing the present societal and climate challenges. Considerable attention is given to the utilisation of alternative sources of proteins, fibres and oils/fats, due to the increasing world population…

The People's Dispensary for Sick Animals (PDSA) intends to procure a new contractual arrangements for the supply and support of veterinary pharmaceutical products to its network of Pet Hospitals and operational sites across the United Kingdom. This Expression of Interest (EOI) relates to a forthcoming procurement for veterinary pharmaceutical products, consumables, pet foods and associated support products. The procurement is intended to establish contractual arrangements with suitably qualified suppliers capable of supporting PDSA's national clinical operations. This EOI is intended only for organisations with demonstrable capability and experience in the manufacture, supply, distribution, or authorised marketing of veterinary pharmaceuticals within regulated UK supply environments. PDSA is seeking suppliers capable of supporting one or more categories of veterinary pharmaceutical products. Suppliers may express interest in individual product groups, therapeutic categories, or broader portfolio arrangements. PDSA is seeking interest from suppliers who can evidence: • Holding the appropriate regulatory authorisations for the activities they propose to undertake, including (where applicable) relevant Veterinary Medicines Directorate (VMD) licences, marketing authorisations, manufacturing authorisations, wholesale dealer authorisations, or equivalent regulatory approvals; • Experience of operating within regulated and audited pharmaceutical supply chains, with established governance, quality assurance, pharmacovigilance, and compliance arrangements; • The ability to maintain continuity of supply, manage shortages proactively, and support robust forecasting and supply planning arrangements across the PDSA's entire veterinary healthcare organisation. • Transparent and sustainable commercial models appropriate to a national charity operating under public and ethical scrutiny; • A demonstrable commitment to ethical, responsible, and compliant trading practices, aligned with PDSA's values and statutory obligations; • The ability to support collaborative supplier relationships, including product stewardship, supply continuity planning, and management of product lifecycle changes. This EOI is not intended for organisations without relevant regulatory standing, sector experience, or operational capability to deliver the products and services described. A full Invitation to Tender, including detailed requirements, product specifications, evaluation criteria, and procurement timescales, will be issued in due course to organisations that register their interest and are considered capable of meeting PDSA's requirements. Register interest by contacting tenders@pdsa.org.uk, quoting "Veterinary Pharmaceutical Supply - EOI" in the subject line. Registration of interest does not constitute a commitment by PDSA to invite any organisation to tender, nor does it form part of any pre-qualification or guarantee progression to the ITT stage.